These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34805377)

  • 21. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
    Mosca L; Navar AM; Wenger NK
    J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia.
    Lewis GF; Hegele RA
    Lancet Diabetes Endocrinol; 2022 Feb; 10(2):142-148. PubMed ID: 34922644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?
    Florentin M; Kostapanos MS; Anagnostis P; Liamis G
    Expert Opin Pharmacother; 2020 Jan; 21(1):107-120. PubMed ID: 31738617
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Mild-to-Moderate Hypertriglyceridemia.
    Pulipati VP; Brinton EA; Hatipoglu B
    Endocr Pract; 2022 Nov; 28(11):1187-1195. PubMed ID: 35850450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia.
    Pirillo A; Catapano AL
    Int J Cardiol; 2013 Dec; 170(2 Suppl 1):S16-20. PubMed ID: 23856442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
    Drexel H; Tamargo J; Kaski JC; Lewis BS; Saely CH; Fraunberger P; Dobrev D; Komiyama M; Plattner T; Agewall S; Hasegawa K
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):570-582. PubMed ID: 37328424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertriglyceridaemia: an update.
    Wierzbicki AS; Kim EJ; Esan O; Ramachandran R
    J Clin Pathol; 2022 Dec; 75(12):798-806. PubMed ID: 35710321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story.
    Rhainds D; Brodeur MR; Tardif JC
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1059-1079. PubMed ID: 31752565
    [No Abstract]   [Full Text] [Related]  

  • 37. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
    Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options.
    Bashir B; Ho JH; Downie P; Hamilton P; Ferns G; Datta D; Cegla J; Wierzbicki AS; Dawson C; Jenkinson F; Delaney H; Mansfield M; Teoh Y; Miedzybrodzka Z; Haso H; Durrington PN; Soran H
    Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel emerging therapies in atherosclerosis targeting lipid metabolism.
    Gupta M; Blumenthal C; Chatterjee S; Bandyopadhyay D; Jain V; Lavie CJ; Virani SS; Ray KK; Aronow WS; Ghosh RK
    Expert Opin Investig Drugs; 2020 Jun; 29(6):611-622. PubMed ID: 32363959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.